Emotion suppression + Bromazepam
Bromazepam is known to produce emotion suppression, a cognitive effect. A blunting or flattening of emotional experience in which feelings become muted, distant, or seemingly absent. The individual may recognize intellectually that they should be feeling something in response to a situation — joy at good news, sadness at a loss, anxiety about a threat — yet the emotional charge simply is not there, as though an invisible pane of glass separates them from their own feelings.
About Emotion suppression
Emotion Suppression
Emotion suppression is the experience of a marked reduction in the intensity, range, or accessibility of one's emotional responses. From a first-person perspective, it manifests as a peculiar emotional numbness or flatness — events that would normally provoke strong feelings are met with a calm detachment or indifference. One might watch an emotionally charged film and notice that the scenes which would normally bring tears produce only a mild, distant recognition that sadness would be appropriate. Conversations that would normally trigger anxiety feel strangely neutral. The internal emotional weather becomes overcast and still, neither stormy nor sunny, just a pervasive grey evenness.
At mild levels, emotion suppression feels like emotional resilience — stressors seem less bothersome, and one navigates situations with an unusual equanimity. At moderate levels, it becomes more clearly pathological: positive emotions are blunted along with negative ones, and activities that normally bring pleasure feel hollow or uninteresting. At high levels, the individual may experience a near-complete emotional anesthesia in which they feel functionally incapable of any emotional response, sometimes described as feeling like an automaton or observing life through a thick window. This can be profoundly alienating and, paradoxically, itself distressing at a meta-cognitive level.
Emotion suppression manifests in several distinct patterns. Selective suppression targets primarily negative emotions (anxiety, sadness, fear) while leaving positive emotions relatively intact — this is the therapeutic goal of many anxiolytic and antidepressant medications. Non-selective suppression blunts the entire emotional spectrum indiscriminately, which is more common with higher doses of dissociatives and certain antipsychotics. Dissociative emotional suppression involves a sense of disconnection from one's emotions rather than their outright absence — the feelings may still be there but feel as though they belong to someone else. Anhedonic suppression specifically targets the capacity for pleasure and reward while other emotions may remain partially accessible.
The pharmacological mechanisms underlying emotion suppression are diverse. Dissociatives (ketamine, PCP, DXM) produce emotional blunting through NMDA receptor antagonism, which disrupts glutamatergic signaling in circuits connecting the prefrontal cortex to the limbic system. Opioids suppress emotional pain through mu-opioid receptor activation in the amygdala and anterior cingulate cortex, regions critical for emotional processing. Benzodiazepines dampen emotional reactivity through GABAergic enhancement in the amygdala. SSRIs, with chronic use, can produce emotional blunting through serotonergic desensitization of 5-HT2 receptors, reducing the dynamic range of emotional responses.
Emotion suppression is most strongly associated with dissociatives (ketamine, DXM, PCP, nitrous oxide), opioids (morphine, heroin, oxycodone), benzodiazepines, antipsychotics, and SSRIs with chronic use. It can also occur with high doses of cannabis (particularly in experienced users), during the comedown phase of stimulants and entactogens, and paradoxically during overwhelming psychedelic experiences as a protective psychological response.
While emotion suppression can provide temporary relief from emotional distress, chronic or substance-induced emotional numbing carries significant psychological risks. The inability to access emotions impairs decision-making, damages interpersonal relationships, and can mask developing mental health conditions. In the context of opioid or benzodiazepine use, emotional suppression is intimately linked to the reinforcement cycle of dependence — the relief from emotional pain becomes the primary motivation for continued use. Individuals who notice persistent emotional blunting extending beyond the acute effects of a substance should consider this a warning sign of developing psychological dependence or an underlying mood disorder requiring attention.